Finnish Medicines Agency, P.O. Box 55, 00301 Helsinki, Finland.
Health Policy. 2013 Jul;111(2):200-5. doi: 10.1016/j.healthpol.2013.04.005. Epub 2013 May 14.
The Finnish Medicines Agency was mandated to develop a national medicines information strategy. The objectives of this study were to assess stakeholders' views on strengths, challenges and opportunities in medicines information for the basis of the strategy.
Interviews among stakeholder representatives (n=28) from patient organizations, universities, pharmacies, and professional associations in medicine, pharmacy and nursing were conducted in 2011. Interview memos were thematically content-analysed. The draft strategy was finalized through two public hearings and a public consultation.
Stakeholders highlighted the need to increase cooperation and coordination in medicines information. The existence of numerous quality- and evidence-based medicines information sources was identified as a strength; although the stakeholders were concerned about the fragmented and unequal access to them. The strengthening of the role of health care professionals in communicating about medicines was seen as an opportunity, but its realization requires improvements in basic and continuing education. Furthermore, the stakeholders emphasized the importance of uniform medicines information regardless of source.
Stakeholders identified multiple strengths, challenges and opportunities in medicines information that were fundamental to developing the national medicines information strategy. An inventory of stakeholder perspectives can be recommended as a tool to support decision-making in pharmaceutical policy.
芬兰药品管理局受命制定国家药品信息战略。本研究的目的是评估利益相关者对药品信息的优势、挑战和机遇的看法,为战略提供依据。
2011 年,对来自患者组织、大学、药房以及医学、药学和护理专业协会的利益相关者代表(n=28)进行了访谈。对访谈记录进行了主题内容分析。通过两次公开听证会和一次公开咨询,最终确定了战略草案。
利益相关者强调需要加强药品信息方面的合作与协调。他们认为存在许多质量和基于证据的药品信息来源是一种优势;尽管他们担心这些资源的获取存在分散和不平等的问题。利益相关者认为,加强医疗保健专业人员在药品宣传方面的作用是一个机会,但要实现这一目标,需要改进基础和继续教育。此外,利益相关者强调了无论信息来源如何,都需要统一的药品信息。
利益相关者确定了药品信息方面的多个优势、挑战和机遇,这些都是制定国家药品信息战略的基础。可以推荐利益相关者观点清单作为支持药物政策决策的工具。